Ocular Therapeutix, Inc. $OCUL Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 431.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 55,496 shares of the biopharmaceutical company’s stock after purchasing an additional 45,061 shares during the quarter. SG Americas Securities LLC’s holdings in Ocular Therapeutix were worth $649,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of OCUL. Nisa Investment Advisors LLC increased its position in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,392 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Ocular Therapeutix by 17.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 893 shares in the last quarter. Trust Co. of Vermont grew its stake in Ocular Therapeutix by 16.1% in the 2nd quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 1,000 shares during the last quarter. Marex Group plc purchased a new position in Ocular Therapeutix during the 2nd quarter valued at about $115,000. Finally, Rafferty Asset Management LLC increased its holdings in Ocular Therapeutix by 21.2% during the 2nd quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 2,343 shares in the last quarter. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Thursday, October 2nd. Needham & Company LLC restated a “buy” rating and set a $20.00 price objective on shares of Ocular Therapeutix in a research report on Monday, December 8th. Robert W. Baird increased their target price on Ocular Therapeutix from $17.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, October 3rd. Piper Sandler raised their price target on Ocular Therapeutix from $21.00 to $31.00 and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Wednesday, November 5th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.56.

Ocular Therapeutix Stock Down 2.6%

Shares of NASDAQ:OCUL opened at $11.12 on Friday. The stock’s 50-day moving average price is $12.34 and its two-hundred day moving average price is $12.03. The company has a current ratio of 7.85, a quick ratio of 7.78 and a debt-to-equity ratio of 0.27. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $16.44. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -7.72 and a beta of 0.93.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. The company had revenue of $14.54 million during the quarter, compared to the consensus estimate of $14.57 million. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. On average, research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.